Cleveland BioLabs, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

false 0001318641 0001318641 2021-09-01 2021-09-01

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).                                                                

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.03         Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

Effective September 1, 2021, the registrant (the “Company”) changed its corporate name from Cytocom, Inc. to Statera Biopharma, Inc. The name change was effected following approval by the Company’s board of directors through the filing of a Certificate of Amendment to the Company’s Restated Certificate of Incorporation. In accordance with Section 242(b)(1) of the Delaware General Corporation Law, stockholder approval of the name change was not required. A copy of the Certificate of Amendment is attached hereto as Exhibit 3.1 and incorporated by reference herein. The name change does not affect the rights of the Company’s security holders, creditors or suppliers. Following the name change, any stock certificates that reflect the Company’s prior name will continue to be valid. Certificates reflecting the new name will be issued in due course as old stock certificates are tendered for exchange or transfer to our transfer agent.

 

Also effective September 1, 2021, the Company’s common stock began trading on The Nasdaq Capital Market with the symbol “STAB” and it is represented by a new CUSIP number, 857561 104.

 

Item 9.01         Financial Statements and Exhibits

 

(d)         Exhibits

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.